Aromasin

This page contains recent news articles, when available, and an overview of Aromasin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Aromasin (when available)

Pharmacology and use:
aromatase is an enzyme that converts hormones to estrogen in the body's adrenal glands. The aromatase inhibitors (AIs) are drugs that reduce estrogen levels by blocking the action of aromatase in the adrenal glands. The selective AIs (SAIs) selectively reduce levels of estrogen without interfering with levels of other steroid hormones that are produced by the adrenal gland. Drugs in this class include anastrozole (ArimidexÆ), letrozole (FemaraÆ) and exemestane (AromasinÆ). For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Mechanism Of Action:
Breast cancer cell growth may be estrogen-dependent. Aromatase (exemestane) is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromatase inhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breast cancer. Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation, an effect also known as "suicide inhibition". Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme.

News Articles on Exemestane

Cramer's Mad Money - Agnico Eagle's Golden Disappointment (11/2/09)  -  ‎Nov 3, 2009‎
Pfizer has 22 cancer drugs, including Aromasin for breast cancer, Camptoar for colorectal cancer, and its most promising treatment, Stutent, which inhibits ... Seeking Alpha (blog)

Jim Cramer Names His Best Picks for Cancer Cures (BMY, IMGN, PFE, DNDN, EXEL)  -  ‎Nov 9, 2009‎
Currently, Pfizer has 22 cancer drugs including Aromasin, used for Breast Cancer treatment; Sutent, a drug that limits blood into tumors; and Campotar, ... Benzinga

REG-Pfizer Inc Pfizer Reports Third-Quarter 2009 Results  -  ‎Oct 20, 2009‎
Examples of products in this business unit include, but are not limited to, Sutent and Aromasin. All revenues for such products are allocated to the ... Reuters

A Cure for Cancer?  -  ‎Nov 4, 2009‎
Pfizer has 22 cancer drugs, the top performers being Aromasin for breast cancer, Camptoar for colorectal cancer and Sutent, a small molecule drug that ... CNBC

Aromasin nel trattamento del tumore al seno a insorgenza precoce  -  ‎Nov 4, 2009‎
...portato allo sviluppo degli inibitori dell'aromatasi di terza generazione, Anastrozolo ( Arimidex ), Letrozolo ( Femara ) ed Exemestane ( Aromasin ). ... XagenaSalute

Una rosa podría ayudar a salvar la vida de mujeres dominicanas  -  ‎Oct 20, 2009‎
Tiene a disposición de médicos y pacientes Aromasin, que es un inhibidor de aromatasa, comúnmente utilizado en mujeres posmenopáusicas cuyos tumores crecen ... Periódico Primicias

Low-dose estrogen may help if breast cancer recurs  -  ‎Aug 18, 2009‎
They include Pfizer's Aromasin, Novartis's Femara, and AstraZeneca Plc's Arimidex. "The women in the study had all experienced a relapse while on Reuters

乳癌藥物Femara與Tamoxifen的比較  -  ‎Aug 26, 2009‎
Femara屬於芳香酶抑制劑的一種，這類藥物還包括Arimidex與Aromasin，其作用是抑制aromatase enzyme的活性。這項新的研究顯示，大約經�?�六年，�?��?用Femara或是先臺灣新浪網

�?и�?ки дози е�?троген полезни при повторен рак на гърдата  -  ‎Aug 18, 2009‎
Това �?а "Aromasin" на "Пфайзер", "Femara" на "�?оварти�?" или "Arimidex" на "�?�?траЗенека". "Жените в из�?ледването в�?ички �?а изпитали повторение на БГНЕС

Dosis de estrógenos podría ayudar si reaparece cáncer de mama  -  ‎Aug 18, 2009‎
Los investigadores incluyeron Aromasin, de Pfizer, Femara, de Novartis y Arimidex, de AstraZeneca Plc. "Todas las mujeres del estudio habían experimentado Reuters América Latina

Dosis Rendah Estrogen Cegah Kambuhnya Kanker Payudara  -  ‎Aug 19, 2009‎
Semua itu meliputi Aromasin, produksi Pfizer, Femara dari Novartis dan Arimidex dari AstraZeneza Plc. "Semua perempuan di dalam studi tersebut telah Berita8

avodart, vagifem, aromasin or fluoxetine.  -  ‎Jun 30, 2009‎
Many Z may because avodart our avodart your over this all have. avoadrt pharmacies items for file year similar learn from the the countries. На плувка и дъно

Co-pay issue resolved  -  ‎Jun 24, 2009‎
Q. As a breast cancer survivor I must take Aromasin for five years. Two years have gone by and my oncologist sends my prescription to Medco for 30 pills at MiamiHerald.com

Problema de copagos resuelto  -  ‎Jun 29, 2009‎
Soy una sobreviviente de cáncer de seno, y tengo que tomar Aromasin durante cinco años. Ya han pasado dos años, y mi oncólogo envía mi prescripción a Medco El Nuevo Herald

乳腺癌新�?�  -  ‎Jun 24, 2009‎
...癌新�?�包括了和激素治疗�?�物他莫昔芬�?瑞�?得（Arimidex）�?弗隆（Femara）�?�用；和阿诺新（Aromasin）等芳香酶抑制剂�?�用；和赫赛汀（Herceptin）�?�用治疗等。医盟网健康资讯

Pharma Companies Hit With Warnings for Search Marketing  -  ‎Apr 8, 2009‎
...“The sponsored links cited in this letter are misleading because they make representations and/or suggestions about the efficacy of Aromasin, Caduet, PharmExec.com

FDA Warns World's Largest Drug Firms Over Internet Ads  -  ‎Apr 3, 2009‎
Pfizer has received warnings for sponsored ads related to Aromasin, Caduet, Chantix, Detrol, Lyrica and Celebrex. The company said it "recognizes the CNNMoney.com

Live for today  -  ‎Mar 3, 2009‎
The oncologist recommended switching medication to Aromasin and return in two months. Laverne's sister, Linda Hatton, a registered nurse, and Laverne's Post Searchlight

Lucha contra el cancer de mama  -  ‎Mar 6, 2009‎
...investigación y desarrollo en el área oncológica y además ofrece alternativas de tratamiento hormonales para cáncer de mama como Aromasin (Exemestano), El Porvenir

�?��?乳癌》轉移性乳癌的治療  -  04 Feb 2009
...至於�?�經後的乳癌病患則�?��?�擇芳香環轉化酶抑制劑(如:Arimidex,Femara,Aromasin 中時電�?報,

Advances in the Treatment of Early-stage Breast Cancer: A Report ...  -  Feb 3, 2009
However, as in the BIG 1-98 trial, planned interim analysis revealed improved outcomes for Aromasin, resulting in all patients on tamoxifen crossing over to Cancer Consultants,

Growth Factor Associated With More Deadly Breast Tumors  -  Feb 3, 2009
Currently, the Breast Center is studying the effects of an IGF receptor antibody combined with a drug called exemestane (Aromasin® or an aromatase inhibitor RedOrbit,

Treatments for early breast cancer  -  Jan 21, 2009
Aromatase inhibitors include anastrozole (brand name Arimidex), exemestane (brand name Aromasin) and letrozole (brand name Femara). More. guardian.co.uk,

New Therapies Vie for Role in Breast Cancer  -  Jan 23, 2009
The IGF-R1 inhibitor CP-751871 is being evaluated with exemestane (Aromasin) in an ongoing randomized clinical trial involving patients with ER-positive MedPage Today,

Hormones Part I: Hormonal Balance is the Key to Vibrant Health for ...  -  Jan 16, 2009
...typically placed on Tamoxifin or other aromatase inhibitors such as arimidex, femara and aromasin, drugs that often produce debilitating side effects. Natural News.com,

Pfizer Reports Fourth-Quarter and Full-Year 2008 Results and 2009 ...  -  Jan 26, 2009
ONCOLOGY 2551 2640 (3) 537 972 (45) 2014 1668 21 SUTENT 847 581 46 254 237 7 593 344 72 CAMPTOSAR 563 969 (42) 82 539 (85) 481 430 12 AROMASIN 465 401 MarketWatch (press release)

First Molecular-Level Enzyme Images Could Improve Breast-Cancer ...  -  Jan 20, 2009
Commercial AIs include Femara, Aromidex and Aromasin. But although aromatase has been studied for almost 40 years, its estrogen-producing process has OBBeC.com,

Femara®, Aromasin® Superior to Tamoxifen in Early Breast Cancer  -  Dec 19, 2008
Results from two separate studies have indicated that the aromatase agents Femara® (letrozole) and Aromasin® (exemestane) improve outcomes compared with Cancer Consultants,

Pfizer Announces Results from Trial of AROMASIN in Postmenopausal ...  -  Dec 11, 2008
TEAM was originally designed in 2001 as a comparison of 5 years of upfront AROMASIN® (exemestane tablets) vs. tamoxifen. In 2004, based on results of WELT ONLINE,

Aromasin (exemestane) Shows Some Advantages Over Tamoxifen As ...  -  Dec 17, 2008
Aromasin (exemestane) rather than the standard adjuvant therapy tamoxifen after initial therapy (surgery plus chemotherapy and/or radiotherapy). Medical News Today,

NEW LANDMARK TRIAL INDICATES BENEFIT OF AROMASIN (EXEMESTANE)  -  Dec 15, 2008
...“TEAM convincingly demonstrates that distant recurrence, a feared outcome after surgery, is reduced in the first few years after diagnosis when Aromasin is PharmiWeb.com (press release),

Treatment Updates  -  Dec 23, 2008
The TEAM trial asked whether five years of Aromasin (exemestane) or tamoxifen works better as single-agent therapy after surgery. The first analysis of this Curetoday.com (press release),

Osteoporosis Drug Seems to Shrink Breast Tumors  -  Dec 11, 2008
...receptor- and/or progesterone receptor-positive breast cancer who took the aromatase inhibitor exemestane (Aromasin) had a 15 percent relative reduction Washington Post,

XplosiveStocks.com: Pfizer (NYSE:PFE) Hot Stock on the Move!  -  Dec 15, 2008
TEAM was originally designed in 2001 as a comparison of 5 years of upfront AROMASIN(R) (exemestane tablets) vs. tamoxifen. In 2004, based on results of Trading Markets (press release),

화�?��? 유방암 치료제 '아로마신' 타목시펜보다 효과 떨어져  -  Dec 11, 2008
...［메디컬투�?��?� 곽�?��?� 기�?］ 화�?��?�?� 유방암 치료제 '아로마신(Aromasin : exemestane)'�?� 호르몬�?수성조기유방암�?� 발병한 �??경 여성�?서 수명�?� 늘리는�?� 있어서 마�?��?��?�리,

Causes Of Bone Loss In Breast Cancer Survivors Include Cancer ...  -  Nov 20, 2008
Aromatase inhibitors include letrozole (trade name, Femara), anastrazole (Arimidex) and exemestane (Aromasin). Researchers reviewed charts of 238 Science Daily (press release)

Why Antiestrogen Side Effects May Predict Decreased Risk of Breast ...  -  Nov 5, 2008
Some advice: if you have recently started therapy with tamoxifen or an aromatase inhibitor (including Arimidex, Femara and Aromasin) and are experiencing CTV.ca,

Realizan encuentro prevención cáncer de mama  -  Oct 27, 2008
Pfizer Oncología tiene a disposición de médicos y pacientes AROMASIN, que es un inhibidor de aromatasa, es decir, un medicamento comúnmente utilizado en Diario Digital RD,

Breast cancer awareness  -  20 Oct 2008
...women with early or advanced breast cancer that is hormone-receptor positive: letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin). GoErie.com,

Best cancer care 'not guaranteed'  -  Oct 5, 2008
AIs, such as the drug Aromasin, suppress production of the female sex hormone oestrogen, which fuels the growth of most breast tumours. The Press Association

Battling Breast Cancer  -  Oct 17, 2008
...women with early or advanced breast cancer that is hormone-receptor positive: letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin). Providence Journal,

UK women with breast cancer at risk of missing out on optimal care  -  Oct 6, 2008
Exemestane (Aromasin) is indicated for the adjuvant treatment of postmenopausal women with oestrogen-receptor positive invasive early breast cancer, PharmiWeb.com (press release),

Propaganda Campaign Against Estrogen Benefits Pharmaceutical Companies  -  Oct 3, 2008
Aromasin goes for $460.59 for 150, and Femara's cost is $509.63 for 150. Convincing you that natural hormone replacement is bad for you will also ensure Natural News.com,

Acupuncture May Help With Side Effects of Hormone Therapy, Study Finds  -  Oct 11, 2008
And drugs called aromatase inhibitors – letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin) -- have been approved to treat both ACS News Center,

Surviving To Share  -  Oct 13, 2008
Today I watch my diet, exercise for 30 minutes a day, I take a pill called Aromasin daily and go for diagnostic mammograms yearly. Rome News-Tribune,

Geen compensatie voor kankerpatiënten met hormoongevoelige medicatie  -  Oct 6, 2008
...(Tamoxifen) letrozole (Femara), exemestane (Aromasin) en anastrozole (Arimidex) ook op de lijst van medicijnen zou staan. Dit blijkt niet het geval. Nieuwsbank (abonnement),

Health Watch: Breast Cancer Survivor Issues  Aug 27, 2008
...the chance of their cancer coming back if they take a pill that blocks estrogen, such as tamoxifen or more recently: arimidex, femara and aromasin.WCBS-TV New York,

Data to Be Presented At ESMO 2008 Highlight Pfizer Commitment to ...  Sep 8, 2008
Data on the following compounds will also be presented at ESMO: Aromasin(®) (exemestane), Campto(®) (irinotecan HCl), axitinib and tremelimumab.WELT ONLINE,

Growth Factor Predicts Poor Outcome In Breast Cancer  Aug 29, 2008
Currently, the Breast Center is studying the effects of an IGF receptor antibody combined with a drug called exemestane (Aromasin® or an aromatase inhibitorScience Daily (press release)

Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report  Aug 27, 2008
Merck/Ariad (deforolimus), Novartis (Zometa, Femara, everolimus, patupilone, TAE-266), OSI (OSI-906), Pfizer (Aromasin, Sutent, Tarceva, CP-751871),MarketWatch

Bisphosphonate Thwarts Bone Loss from Breast Cancer Endocrine Therapy  Aug 20, 2008
The patients were randomized to three years of treatment with goserelin plus anastrozole (Aromasin) or tamoxifen. Patients in both groups were furtherMedPage Today,

�?��?린 닮�?� 성장�?��? '유방암' 예후 결정  Sep 2, 2008
...연구팀�?� 현재 유방암�? 대해 '아로마신(Aromasin:exemestane)'�?��?�는 약물과 IGF 수용체 항체를 병행 치료�?� 효과를 연구중�?�다. 메디컬투�?��?� 조고�?� 기�?.마�?��?��?�리,

From hoops coach to cop, and back again  -  Aug 3, 2008
She continues to take Aromasin, a pill that decreases the chance of cancer recurrence. "Supposedly when you get five years away from the cancer, Arizona Daily Star,

Pfizer Reports Second-Quarter 2008 Results  -  Jul 23, 2008
ONCOLOGY 650 652 - 109 239 (55) 541 413 31 SUTENT 211 146 45 60 61 (2) 151 85 80 CAMPTOSAR 137 241 (43) 6 130 (96) 131 111 19 AROMASIN 117 92 26 32 28 FOXBusiness

Zoledronic Acid Significantly Reduced Relapse in Early Breast Cancer  -  Jun 17, 2008
...exemestane (Aromasin, Pfizer), and the BIG 3-02 study, which is comparing an LHRH agonist plus tamoxifen with an LHRH agonist and exemestane. Abkhazia,

Zolendronic Acid Significantly Reduced Relapse in Early Breast Cancer  -  02 Jun 2008
...exemestane (Aromasin, Pfizer), and the BIG 3-02 study, which is comparing an LHRH agonist plus tamoxifen with an LHRH agonist and exemestane. Medscape (subscription)

Early Breast Cancer:  -  May 16, 2008
A recent study has shown that switching to AROMASIN after 2 to 3 years of tamoxifen can help reduce the risk of breast cancer recurrence compared with WebMD

Certain Age: Body shrinkage just not an option  -  May 5, 2008
The medication I take to prevent a recurrence of breast cancer, Aromasin, eats away at calcium and so I am supposed to take supplements. The State,

New Pfizer Data in Lung Cancer, Ewing's Sarcoma, Prostate Cancer ...  -  May 16, 2008
Data on the following compounds will also be presented at ASCO 2008: Aromasin ® (exemestane), Camptosar ® (irinotecan HCl), CP-868596, PF-3512676, Earthtimes (press release),

Deciding on breast cancer treatment: Tamoxifen versus aromatase ...  -  May 13, 2008
The FDA has approved three aromatase inhibitors: anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara). Tamoxifen is effective in both pre- Gather.com,

Specific Gene Mutations May Affect Response to Tamoxifen in Breast ...  -  May 12, 2008
Newer agents, however, referred to as aromatase agents (Femara® [letrozole], Arimidex® [anastrozole], and Aromasin® [exemestane]), are now commonly used for Cancer Consultants,

EBBC: Aromatase Inhibitors Do Not Increase Cardiovascular Risks  -  Apr 18, 2008
An analysis of several trials comparing anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) with tamoxifen or placebo found no added risk MedPage Today,

Survivors of the Week  -  Apr 8, 2008
I did take the Tamoxifen for four years and am now on Aromasin. My cancer was estrogen fed so there is a need for me to be on some type of medication to The Topsail Advertiser,

Study: More Women Can Cut Cancer Relapse Risk  -  10 Mar 2008
A third study, involving 1598 patients, found that a different aromatase inhibitor, known as exemestane or by the brand name Aromasin, was equally effective Washington Post,

Femara cuts cancer recurrence even if started late  -  10 Mar 2008
Pfizer Inc makes an aromatase inhibitor called exemestane, which it sells under the brand Aromasin, and AstraZeneca Plc makes anastrozole, sold under the Scientific American

Sask. covers 18 cancer drugs in group's study  -  Feb 13, 2008
For example, Saskatchewan doesn't pay for Arimidex, Femara and Aromasin to treat breast cancer but they are fully funded in BC and Alberta. Canada.com,

Cancer Advocacy Coalition of Canada releases annual Report Card On ...  -  Feb 12, 2008
...account for the majority of private claims and costs: Xeloda, Temodol, Gleevec, Tarceva and three aromatase inhibitors: Femara, Aromasin and Arimidex. Canada NewsWire (press release),

Brand Names/Synonyms:
Aromasin is also known by the following brand names and/or synonyms:
Aromasin; EXEMESTANE; Exemestance; Exemestane; Exemestane [Inn]; Exemestane [Usan:Inn:Ban]; Exemestano [Inn-Spanish]; Exemestanum [Inn-Latin]

Drug Category:
Aromasin is categorized under the following by the FDA: Antineoplastic Agents; ATC:L02BG06

Dosage Forms:
tablets

Absorption:
42%

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
10,13-dimethyl-6-methylidene-7,8,9,10,11,12,13,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.